Gain Therapeutics Net Worth
Gain Therapeutics Net Worth Breakdown | GANX |
Gain Therapeutics Net Worth Analysis
Gain Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Gain Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Gain Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Gain Therapeutics' net worth analysis. One common approach is to calculate Gain Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Gain Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Gain Therapeutics' net worth. This approach calculates the present value of Gain Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Gain Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Gain Therapeutics' net worth. This involves comparing Gain Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Gain Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Gain Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gain Therapeutics' net worth research are outlined below:
| Gain Therapeutics generated a negative expected return over the last 90 days | |
| Gain Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 55.18 K. Net Loss for the year was (22.27 M) with loss before overhead, payroll, taxes, and interest of (7.66 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Gain Therapeutics Buy Rating Reaffirmed at HC Wainwright - MarketBeat |
Gain Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gain Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gain Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Gain Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gain Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gain Therapeutics backward and forwards among themselves. Gain Therapeutics' institutional investor refers to the entity that pools money to purchase Gain Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2023-12-31 | 27.6 K | Raymond James & Associates | 2023-12-31 | 23.8 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 15.9 K | Ubs Group Ag | 2023-12-31 | 14 K | Millennium Management Llc | 2023-12-31 | 12.8 K | Xtx Topco Ltd | 2023-12-31 | 11.5 K | Advisor Group Holdings, Inc. | 2023-12-31 | 10 K | Tower Research Capital Llc | 2023-12-31 | 4.9 K | Creekmur Asset Management Llc | 2023-12-31 | 4.4 K | Greenlight Capital, Inc | 2023-12-31 | 588.4 K | Royal Bank Of Canada | 2023-12-31 | 200.2 K |
Follow Gain Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gain Therapeutics's market, we take the total number of its shares issued and multiply it by Gain Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Gain Therapeutics' profitablity
Gain Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Gain Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Gain Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Gain Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Gain Therapeutics' profitability requires more research than a typical breakdown of Gain Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.21) | (1.27) | |
| Return On Capital Employed | (1.63) | (1.55) | |
| Return On Assets | (1.20) | (1.26) | |
| Return On Equity | (1.77) | (1.68) |
When accessing Gain Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Gain Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gain Therapeutics' profitability and make more informed investment decisions.
The data published in Gain Therapeutics' official financial statements usually reflect Gain Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Gain Therapeutics. For example, before you start analyzing numbers published by Gain accountants, it's critical to develop an understanding of what Gain Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Gain Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gain Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Gain Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gain Therapeutics. Please utilize our Beneish M Score to check the likelihood of Gain Therapeutics' management manipulating its earnings.
Evaluate Gain Therapeutics' management efficiency
Gain Therapeutics has return on total asset (ROA) of (0.6514) % which means that it has lost $0.6514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4157) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.27 in 2024. Return On Capital Employed is likely to rise to -1.55 in 2024. At this time, Gain Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.97 | 1.03 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 0.95 | 1.02 | |
| Enterprise Value Over EBITDA | (1.43) | (1.50) | |
| Price Book Value Ratio | 3.38 | 3.55 | |
| Enterprise Value Multiple | (1.43) | (1.50) | |
| Price Fair Value | 3.38 | 3.55 | |
| Enterprise Value | 31.8 M | 30.2 M |
The analysis of Gain Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Gain Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Gain Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 625.4774 | Revenue 55.2 K | Quarterly Revenue Growth (1.00) | Revenue Per Share 0.004 | Return On Equity (1.42) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gain Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gain Therapeutics Corporate Filings
| 26th of April 2024 Other Reports | ViewVerify | |
8K | 8th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 1st of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 2nd of January 2024 Other Reports | ViewVerify |
Gain Therapeutics Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Gain Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Gain Therapeutics Corporate Management
Elected by the shareholders, the Gain Therapeutics' board of directors comprises two types of representatives: Gain Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gain. The board's role is to monitor Gain Therapeutics' management team and ensure that shareholders' interests are well served. Gain Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gain Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gianluca Fuggetta | Principal Reporting | Profile | |
| Xavier Barril | Chief Officer | Profile | |
| Joanne Taylor | Senior Research | Profile | |
| Terenzio PharmD | Senior Operations | Profile | |
| Salvatore Calabrese | CFO Sec | Profile | |
| Khalid Islam | Founder Chairman | Profile |
How to buy Gain Stock?
The net worth of Gain Therapeutics is the difference between its total assets and liabilities. Gain Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Gain Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Gain Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Gain Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Gain Therapeutics stock.Already Invested in Gain Therapeutics?
The danger of trading Gain Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Gain Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Gain Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Gain Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Gain Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Gain Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Gain Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Gain Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Gain Stock analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.004 | Quarterly Revenue Growth (1.00) | Return On Assets (0.65) | Return On Equity (1.42) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.